GlassScriptPhysician profile
Richard J Arrigo
NPI 1669677811
$120,066.69
in general payments reported to CMS, 2019-2025
11 companies · $87K in 2025
The $87K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2021: $25.84 · 2022: $366 · 2023: $12K · 2024: $21K · 2025: $87K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $104K · Travel and Lodging: $10K · Food and Beverage: $4,639 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $104,258.86 |
| Travel and Lodging | $10,396.60 |
| Food and Beverage | $4,639.37 |
| Education | $134.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $87,716.24 | 2023-2025 | Omvoh |
| Janssen Biotech, INC. | $29,543.44 | 2024-2025 | Tremfya, Stelara |
| Abbvie INC. | $733.34 | 2021-2025 | Skyrizi, Rinvoq |
| Olympus Corporation of The Americas | $646.60 | 2023-2024 | Single Use Aspiration Needle Na-U200h |
| Boston Scientific Corporation | $424.13 | 2019-2025 | General - Hemostasis, Overstitch Endoscopic Suturing System |
| Phathom Pharmaceuticals, INC. | $330.07 | 2024 | Voquezna |
| Gilead Sciences, INC. | $296.71 | 2022-2025 | Livdelzi |
| Madrigal Pharmaceuticals | $135.56 | 2024-2025 | Rezdiffra, Resmetirom |
| E.R. Squibb & Sons, L.L.C. | $120.29 | 2022 | |
| Pfizer INC. | $108.89 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Arrigo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.